Tarsier Pharma Management
Management criteria checks 2/4
Tarsier Pharma's CEO is Daphne Haim-Langford, appointed in Jan 2016, has a tenure of 10.5 years. directly owns 2.46% of the company’s shares, worth $497.49K. The average tenure of the management team and the board of directors is 9.9 years and 7.4 years respectively.
Key information
Daphne Haim-Langford
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.5yrs |
| CEO ownership | 2.5% |
| Management average tenure | 9.9yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
CEO
Daphne Haim-Langford (52 yo)
Dr. Daphne Haim-Langford, Ph D., is Chairman of Tarsier Pharma from June 2020 and serves as its Chief Executive Officer from 2016 and is Founder. She serves as a Director of keepMED Ltd.(formerly known as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.5yrs | no data | 2.46% $ 497.5k | |
| Chief Financial Officer | 10.4yrs | no data | no data | |
| Chief Operating Officer | 9.3yrs | no data | 0.20% $ 40.2k | |
| Chief Medical Officer | 9.3yrs | no data | 0.10% $ 20.2k | |
| Head of Chemistry | no data | no data | no data |
Experienced Management: TARX's management team is seasoned and experienced (9.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.1yrs | no data | 2.46% $ 497.5k | |
| Independent Non-Executive Director | 7.3yrs | no data | 0.044% $ 8.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 8.5yrs | no data | 0.044% $ 8.9k | |
| Director | 7.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: TARX's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 13:48 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tarsier Pharma Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.